MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Fri Jun 28 00:00:00 GMT-05:00 2024
NEW
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Wed Jun 26 00:00:00 GMT-05:00 2024
NEW
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Sun Jun 02 00:00:00 GMT-05:00 2024
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Mon May 27 00:00:00 GMT-05:00 2024
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Tue May 21 00:00:00 GMT-05:00 2024
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Mon Apr 29 00:00:00 GMT-05:00 2024
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Fri Apr 05 00:00:00 GMT-05:00 2024
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Wed Apr 03 00:00:00 GMT-05:00 2024
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Tue Apr 02 00:00:00 GMT-05:00 2024
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)